Addex Therapeutics Announces 2025 Financial Results Call
Upcoming Financial Results Announcement from Addex Therapeutics
Geneva, Switzerland - Addex Therapeutics (SIX/NASDAQ: ADXN), a biopharmaceutical company making significant strides in treating neurological disorders, is gearing up to share its Half-Year and Second Quarter 2025 Financial Results. The official announcement is expected on September 30, 2025, followed by a conference call on October 1, 2025, to engage with investors, analysts, and media representatives.
Details on the Announcement
The conference call will have Tim Dyer, the Chief Executive Officer, and Mikhail Kalinichev, the Head of Translational Science, at the helm. They will detail the outcomes of the financial results along with a comprehensive business update while also diving into the Addex product pipeline, which is increasingly gaining attention in the biopharmaceutical landscape.
How to Join the Conference Call
Interested participants should register ahead of time to secure their place in the conference call. Upon registration, each participant will receive a set of Participant Dial-in numbers along with a unique Personal PIN, which is necessary for accessing the call.
Accessing the Call
In the crucial 10 minutes leading up to the start of the call, participants are advised to utilize the conference access information provided via email during registration. For convenience, participants can opt for the 'call me' feature rather than dialing the closest number. This simplifies the process, making it neater and more efficient for everyone involved.
About Addex Therapeutics
Addex Therapeutics is at the forefront of developing innovative small molecule allosteric modulators aimed at addressing various neurological disorders. Their key drug candidate, dipraglurant, functions as an mGlu5 negative allosteric modulator (NAM) and is currently being assessed for its potential in brain injury recovery, focusing on post-stroke and traumatic brain injury rehabilitation.
Strategic Partnerships and Initiatives
In addition to their lead candidate, Addex has entered into fruitful partnerships, such as with Indivior, targeting GABAB PAM drug candidates aimed at treating substance use disorders. Indivior has successfully navigated through IND enabling studies, marking a significant step forward in this initiative.
The Expanding Portfolio of Addex
The company is also making strides in an independent GABAB PAM program focused on addressing chronic cough, showcasing their diversified approach to neurological and related disorders. Moreover, Addex holds a substantial equity interest in a private spin-out company, Neurosterix LLC, advancing a portfolio centered on allosteric modulator programs. These programs encompass exciting candidates like M4 PAM for schizophrenia as well as mGlu7 NAM for mood disorders and mGlu2 NAM targeting mild neurocognitive disorders.
Global Presence and Stock Information
Addex's shares are openly traded on both the SIX Swiss Exchange and the NASDAQ Capital Market, carrying the ticker symbol “ADXN” on each platform. This dual listing reinforces their commitment to transparency and accessibility in the financial markets. For more detailed insights into their innovative work and current projects, interested parties are encouraged to visit their website.
Frequently Asked Questions
1. When will Addex Therapeutics report its 2025 financial results?
Addex Therapeutics will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025.
2. Who will be presenting during the conference call?
Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will present during the call.
3. What is the primary focus of Addex Therapeutics?
Addex Therapeutics focuses on developing novel small molecule allosteric modulators for neurological disorders.
4. Where can investors find more information about Addex Therapeutics?
Investors can visit the Addex Therapeutics website for more detailed information about their projects and initiatives.
5. What ticker symbol do Addex shares trade under?
Addex shares are traded under the ticker symbol “ADXN” on both the SIX Swiss Exchange and the NASDAQ Capital Market.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
